Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(29 sites)
United States
USC Norris Comprehensive Cancer Center, Los Angeles, California University of Chicago Medicine, Chicago, Illinois University of Louisville James Graham Brown Cancer Center, Louisville, Kentucky Cayuga Cancer Center, Ithaca, New York Levine Cancer Center, Charlotte, North Carolina Atrium Health Wake Forest Baptist Center, Winston-Salem, North Carolina Taylor Cancer Research Center, Maumee, Ohio Brown University Health, Providence, Rhode Island Prisma Health Cancer Institute - Multidisciplinary Center, Greenville, South Carolina University of Virginia Emily Couric Clinical Cancer Center, Charlottesville, Virginia Virginia Cancer Specialists, P.C. - Fairfax, Fairfax, Virginia Australia
Liverpool Hospital, Liverpool, New South Wales Southern Oncology Clinical Research Unit, Bedford Park, South Australia Canada
BC Cancer Center, Kelowna, British Columbia Princess Margaret Cancer Center, Toronto, Ontario McGill University Health Centre (MUHC), Montreal, Quebec France
Hôpital Saint-Antoine - Assistance Publique-Hopitaux de Paris (AP-HP), Paris Centre Hospitalier Universitaire (CHU) de Poitiers, Poitiers South Korea
CHA University-Bundang Medical Centre, Seongnam-si, Gyeonggi-do Korea University Anam Hospital, Seoul Severance Hospital, Seoul Korea University Guro Hospital, Seoul Spain
START Barcelona, Barcelona Hospital Clinico San Carlos, Madrid United Kingdom
Beatson Clinical Research Facility, Glasgow Sarah Cannon Research Institute UK, London The Christie NHS Foundation Trust UK, Manchester